Of the 114 patients, 84 (74%) were histologically diagnosed with non-squamous NSCLC and 88 (77%) were treated with anti-PD-1/PD-L1 antibody monotherapy in second- or later-line settings. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.